duchenn
muscular
dystrophi
dmd
common
form
muscular
dystrophi
involv
progress
deterior
muscl
function
dmd
caus
mainli
frameshift
delet
nonsens
duplic
mutat
dmd
gene
encod
protein
dystrophin
milder
becker
muscular
dystrophi
bmd
typic
result
infram
delet
dmd
gene
allow
express
limit
amount
intern
truncat
function
protein
recent
year
rnatarget
splicecorrect
therapi
antisens
oligonucleotid
ao
dmd
muscl
object
restor
infram
beckerlik
transcript
among
promis
therapeut
approach
treat
dmd
end
system
administr
ao
phosphorodiamid
morpholino
oligom
pmo
target
specif
exon
dmd
gene
shown
restor
read
frame
induc
bodywid
product
partial
function
bmdlike
dystrophin
mous
dog
model
dmd
current
method
shown
promis
safe
phase
ii
trial
pmo
phosphorothio
also
common
ao
target
exon
dmd
pmo
neutral
chemistri
provid
outstand
safeti
characterist
excel
vivo
efficaci
suitabl
human
use
moreov
pmo
use
extens
tool
select
inhibit
gene
express
cell
cultur
model
howev
poor
deliveri
pmo
limit
applic
pmomedi
therapi
dmd
muscular
dystrophi
present
precis
mechan
pmo
entri
dystrophindefici
muscl
fiber
still
unknown
domin
hypothesi
pmo
enter
dystrophindefici
muscl
fiber
result
abnorm
membran
permeabl
socal
leaki
membran
show
embryon
myosin
heavi
chain
emhc
dystrophin
doubleposit
regener
myotub
incorpor
pmo
effici
dmd
exon
wildtyp
wt
mice
vitro
studi
myoblast
suggest
pmo
taken
preferenti
muscl
cell
process
myotub
format
also
test
therapeut
potenti
pmo
treatment
mous
model
chain
merosin
defici
congenit
muscular
dystrophi
activ
muscl
regener
result
support
idea
pmo
entri
muscl
fiber
depend
development
stage
myogenesi
rather
intrins
defect
membran
dystrophinless
muscl
fiber
leakymembran
hypothesi
provid
platform
develop
pmomedi
therapi
varieti
muscular
disord
involv
activ
muscl
regener
examin
effect
system
pmomedi
exon
skip
supplementari
materi
fig
inject
wt
mice
singl
dose
tabl
target
splice
donor
site
exon
dmd
gene
rang
dose
mgkg
two
week
inject
gastrocnemiu
muscl
isol
analyz
revers
chain
reaction
could
detect
skip
band
wt
mice
exon
skip
induc
highli
dosedepend
manner
rang
mgkg
dose
show
approxim
skip
effici
mice
supplementari
materi
fig
investig
mechan
pmo
uptak
muscl
fiber
first
evalu
percentag
central
nucleat
fiber
marker
regener
fiber
across
rang
age
n
age
group
central
nucleat
fiber
appear
around
week
dramat
increas
around
week
reach
week
mice
fig
b
supplementari
materi
fig
next
inject
pmo
bodi
weight
tibiali
anterior
ta
muscl
mice
age
week
induc
exon
skip
fig
evalu
extent
dystrophin
express
immunohistochemistri
two
week
inject
ta
muscl
isol
analyz
immunohistochemistri
percentag
dystrophinposit
fiber
averag
pmo
inject
week
approxim
pmo
inject
week
fig
e
found
percentag
dystrophinposit
fiber
highest
pmo
inject
mice
age
week
muscl
regener
activ
investig
phase
pmo
uptak
administ
bromodeoxyuridin
brdu
drink
water
mgml
day
singl
intramuscular
inject
pmo
bodi
weight
label
newli
regener
fiber
inject
ta
muscl
mice
age
week
mice
kill
week
pmo
inject
ta
muscl
remov
analyz
immunohistochemistri
dystrophin
brdu
dapi
fig
found
dystrophinposit
fiber
could
classifi
two
type
brduposit
smallcalib
fiber
diamet
brduneg
normalcalib
fiber
diamet
week
mice
fig
c
total
number
dystrophinposit
fiber
significantli
higher
mice
inject
pmo
week
week
proport
brduposit
smallcalib
fiber
also
significantli
greater
fig
inject
pmo
mgkg
tail
vein
mice
week
administ
brdu
drink
water
mgml
day
perform
immunohistochemistri
dystrophin
brdu
dapi
week
inject
fig
significantli
larg
number
brduposit
fiber
exclus
express
dystrophin
compar
brduneg
fiber
p
fisher
exact
test
fig
data
suggest
immatur
regener
fiber
call
myotub
could
take
pmo
effici
matur
fiber
studi
evalu
mechan
pmo
entri
smallcalib
brduposit
fiber
induc
synchron
regener
fiber
cardiotoxin
ctx
inject
intramuscularli
ta
muscl
mice
age
week
supplementari
materi
fig
day
ctx
inject
pmo
bodi
weight
target
splice
donor
site
exon
inject
ta
muscl
follow
oral
administr
brdu
mgml
day
fig
two
week
later
ta
muscl
obtain
analyz
immunohistochemistri
western
blot
percentag
dystrophinposit
fiber
immunohistochemistri
fig
c
dystrophin
express
level
western
blot
fig
e
peak
muscl
pmo
inject
day
ctx
inject
histolog
ta
muscl
brdu
emhc
doubleposit
smallcalib
fiber
seen
high
level
day
ctx
inject
supplementari
materi
fig
result
suggest
pmo
taken
effici
emhcposit
smallcalib
fiber
mainli
seen
mice
examin
local
pmo
muscl
cryosect
use
fluoresceinconjug
pmo
fpmo
first
fpmo
bodi
weight
target
splice
donor
site
exon
inject
ta
muscl
mice
age
week
two
week
later
ta
muscl
obtain
analyz
immunohistochemistri
found
pmo
fpmo
could
induc
similarli
effici
exon
skip
dystrophin
express
fiber
membran
supplementari
materi
fig
b
next
investig
whether
fpmo
taken
emhcposit
regener
fiber
ctx
inject
muscl
wt
mice
follow
day
later
inject
fpmo
bodi
weight
target
splice
donor
site
exon
ta
muscl
fig
two
hour
later
mice
kill
ta
muscl
remov
microscop
analysi
clearli
day
ctx
inject
fpmo
enter
smallcaliberregener
fiber
less
normalcalib
fiber
peripher
nuclei
fig
next
pmo
mgkg
target
splice
donor
site
exon
inject
tail
vein
wt
mice
day
inject
ctx
ta
muscl
fig
mice
kill
week
later
ta
muscl
remov
analyz
skip
ratio
evalu
day
ctx
inject
respect
fig
e
data
show
smallcaliberregener
fiber
take
pmo
effici
wt
mice
strong
prefer
day
period
maximum
myotub
format
next
analyz
characterist
emhcposit
regener
fiber
induc
ctx
injuri
fig
four
day
ctx
intramuscular
inject
ta
muscl
wt
mice
pmo
mgkg
inject
via
tail
vein
one
hour
later
mice
kill
ta
muscl
remov
analysi
situ
hybrid
phosphatas
probe
reveal
pmo
mainli
present
nucleu
lesser
extent
cytosol
smallcalib
regener
fiber
bare
detect
normalcalib
fiber
peripher
nuclei
fig
c
immunohistochemistri
show
fiber
pmo
detect
express
dystrophin
membran
fig
e
examin
period
pmo
uptak
initi
evalu
express
level
dystrophin
myoblast
differenti
found
express
dystrophin
h
chang
growth
medium
differenti
medium
fig
transduc
myotub
pmo
h
medium
chang
also
test
uptak
period
one
commonli
investig
oligonucleotid
chemistri
use
target
intraexon
site
exon
undifferenti
myoblast
pmo
use
control
h
incub
pmo
cell
collect
analyz
fig
c
skip
ratio
myotub
pmo
transfect
h
follow
medium
chang
respect
fig
skip
ratio
transfect
set
time
period
h
medium
chang
respect
fig
hand
skip
ratio
undifferenti
myoblast
pmo
respect
fig
e
data
support
idea
pmo
effici
taken
muscl
cell
earli
stage
myotub
format
final
perform
pmomedi
exon
skip
mice
anim
model
chaindefici
congenit
muscular
dystrophi
show
sever
dystroph
chang
activ
muscl
regener
skip
exon
murin
gene
mice
correct
open
read
frame
could
lead
product
truncat
chain
fig
first
identifi
effect
ao
sequenc
fibroblast
design
seven
ao
sequenc
target
either
exon
sequenc
junction
murin
exon
fig
sequenc
tabl
transfect
one
two
seven
ao
total
fibroblast
h
incub
analyz
rna
fraction
use
primer
describ
supplementari
materi
figur
among
ao
examin
pmo
plu
shown
capabl
induc
exon
skip
level
approach
highest
among
combin
examin
fig
design
target
exon
site
exon
therefor
inject
combin
two
ao
bodi
weight
ta
muscl
mice
age
day
fifteen
day
later
ta
muscl
obtain
analyz
immunohistochemistri
found
plu
could
induc
exon
skip
fig
confirm
correct
exon
skip
direct
sequenc
product
fig
moreov
fiber
membran
posit
immunohistochemistri
fig
intraperiton
inject
mgkg
total
combin
mice
postnat
age
day
found
plu
could
induc
exon
skip
fig
studi
result
show
trend
toward
improv
life
span
pmotreat
mice
compar
salinetr
mice
fig
data
suggest
potenti
pmomedi
therapi
target
myotub
demonstr
pmo
taken
dystrophin
emhcposit
regener
fiber
wt
mice
also
show
pmo
could
taken
myoblast
earli
stage
myotub
format
result
suggest
appli
pmo
therapi
target
myotub
format
muscular
diseas
confirm
hypothesi
final
show
restor
chain
express
exon
skip
gene
prolong
lifespan
intraperiton
inject
pmo
mice
model
pmo
neutral
chemistri
provid
greatli
decreas
chanc
catastroph
offtarget
antisens
effect
minim
interact
cation
moieti
protein
characterist
pmo
contribut
extrem
low
toxic
suitabl
use
human
pmo
also
use
extens
tool
select
inhibit
gene
express
cell
cultur
model
present
chang
membran
permeabl
dystrophindefici
muscl
membran
socal
leaki
membran
hypothesi
facilit
rout
entri
pmo
myofib
favor
explan
pmo
uptak
hypothesi
base
clinic
evid
dystrophindefici
muscl
fiber
prone
injur
contract
injuri
caus
leakag
solubl
cytoplasm
protein
creatin
kinas
addit
report
intraven
deliv
pmo
show
poor
deliveri
normal
muscl
dystrophindefici
muscl
intramuscular
inject
normal
muscl
show
good
deliveri
evan
blue
low
molecularweight
diazo
dye
high
affin
serum
albumin
cross
skelet
muscl
fiber
normal
mice
mdx
mice
dystrophindefici
anim
model
dmd
show
signific
evan
blue
accumul
skelet
muscl
fiber
howev
hydrophob
plasma
membran
constitut
almost
insurmount
barrier
around
muscl
fiber
result
poor
deliveri
neutral
pmo
prevent
optim
pmomedi
therapi
dmd
muscular
dystrophi
overcom
deliveri
issu
pmo
recent
develop
use
cellpenetr
peptideconjug
pmo
short
cation
peptid
penetr
cell
interact
neg
charg
plasma
membran
may
becom
effect
strategi
reduc
dose
level
administr
frequenc
still
face
issu
offtarget
effect
high
toxic
human
nonspecif
deliveryfacilit
properti
facilit
interact
protein
therefor
import
understand
detail
mechan
pmo
entri
muscl
fiber
improv
poor
deliveri
pmo
optim
therapeut
intervent
dmd
muscular
diseas
studi
found
exon
skip
induc
dose
depend
mice
skip
induc
wt
mice
system
inject
pmo
mgkg
find
conform
leaki
membran
hypothesi
howev
pmo
effici
taken
emhcposit
regener
fiber
day
follow
ctx
inject
ta
muscl
express
dystrophin
muscl
plasma
membran
wt
mice
process
induc
ctx
inject
well
document
follow
ctx
inject
satellit
cell
prolifer
occur
within
day
myogen
differenti
initi
within
day
new
myotub
format
evid
within
day
muscl
architectur
larg
restor
within
day
taken
togeth
vivo
studi
ctx
inject
suggest
pmo
uptak
promin
stage
myogen
differenti
myotub
format
cell
prolifer
stage
also
show
pmo
taken
effici
earli
stage
myotub
format
data
suggest
uptak
mechan
simpli
attribut
chang
membran
permeabl
also
involv
unknown
mechan
earli
stage
myotub
format
report
pmo
intern
uptakepermiss
cell
specif
satur
energi
depend
suggest
receptormedi
mechan
data
suggest
immatur
regener
fiber
call
myotub
could
take
pmo
effici
matur
fiber
consequ
confirm
alreadi
leaki
gateway
dystrophindefici
muscl
fiber
importantli
find
provid
conceptu
advanc
support
idea
pmo
entri
muscl
fiber
depend
development
stage
myogenesi
rather
intrins
defect
dystrophindefici
muscl
membran
leakymembran
hypothesi
provid
platform
develop
pmomedi
therapi
varieti
muscular
disord
involv
activ
muscl
regener
test
potenti
pmo
treatment
target
myotub
format
use
mous
model
mice
polya
cassett
exon
gene
null
mutant
chain
major
compon
basal
lamina
skelet
muscl
peripher
nervou
system
man
chain
consist
six
domain
exon
gene
encod
part
domain
vi
predict
form
ntermin
globular
ln
structur
supplementari
materi
fig
ln
structur
essenti
laminin
aggreg
supramolecular
network
consequ
incorpor
basement
membran
thu
mutat
structur
reduc
capac
polym
format
anoth
merosindefici
mous
mous
harbor
mutat
ln
structur
lead
slightli
reduc
express
chain
partial
lack
structur
thu
display
rel
mild
muscular
dystrophi
peripher
neuropathi
therefor
hypothes
pmomedi
exon
skip
could
act
rescu
mice
studi
success
confirm
recoveri
chain
skip
mutat
exon
data
suggest
pmo
taken
muscl
fiber
may
induc
exon
skip
mice
importantli
pmomedi
exon
skip
real
potenti
becom
effect
therapi
sinc
two
nonsens
mutat
exon
caus
furthermor
half
patient
congenit
muscular
dystrophi
european
popul
mutat
gene
data
could
offer
hope
patient
struggl
diseas
conclus
pmo
taken
preferenti
mous
muscl
cell
myotub
fusion
result
provid
platform
develop
pmomedi
therapi
varieti
muscular
disord
involv
activ
muscl
regener
also
direct
us
interrog
myogen
development
mechan
oppos
defect
membran
function
matur
muscl
fiber
clue
facilit
pmo
deliveri
myopathi
exon
x
chromosomelink
muscular
dystrophi
mice
produc
genetarget
strategi
maintain
facil
mice
backcross
wt
strain
eight
gener
male
mice
age
week
wt
mice
age
week
use
studi
heterozyg
genetarget
mice
polya
cassett
exon
gene
maintain
anim
facil
heterozyg
mice
interbr
obtain
homozyg
mice
genotyp
defici
perform
pcr
tail
genom
dna
pcr
primer
wt
allel
mutant
allel
describ
tabl
mice
show
wt
neoposit
pcr
product
defin
homodefici
experiment
protocol
studi
approv
experiment
anim
care
use
committe
nation
institut
neurosci
nation
center
neurolog
psychiatri
japan
brdu
sigmaaldrich
st
loui
mo
usa
dissolv
pb
gibco
paisley
uk
store
mgml
mice
treat
mgml
brdu
drink
water
day
brdu
solut
prepar
steril
water
protect
light
exposur
chang
daili
ao
target
skip
exon
dystrophin
premrna
splice
mice
design
anneal
splice
site
accord
previous
publish
report
sequenc
synthes
use
pmo
fpmo
gene
tool
llc
philomath
usa
operon
biotechnolog
tokyo
japan
primer
sequenc
analysi
synthes
operon
biotechnolog
list
tabl
local
studi
pmo
dose
bodi
weight
inject
ta
muscl
mice
muscl
obtain
week
intramuscular
inject
analyz
cryosect
immunohistochemistri
system
studi
dose
mgkg
pmo
salin
salin
inject
tail
vein
mice
wt
mice
singli
mice
examin
week
inject
muscl
dissect
immedi
snapfrozen
liquid
nitrogencool
isopentan
store
immunohistochemistri
western
blot
differenti
medium
myotub
incub
day
transfect
pmo
final
concentr
respect
myotub
without
transfect
agent
incub
h
total
rna
extract
cell
frozen
tissu
section
use
trizol
invitrogen
carlsbad
ca
usa
two
hundr
nanogram
total
rna
templat
use
quantitect
revers
transcript
kit
qiagen
crawley
uk
accord
manufactur
instruct
cdna
product
use
templat
pcr
reaction
unit
taqdna
polymeras
qiagen
reaction
mixtur
compris
pcr
buffer
roch
basel
switzerland
mm
dntp
qiagen
primer
primer
sequenc
amplif
cdna
exon
cycl
condit
min
cycl
min
min
min
final
min
intens
pcr
band
analyz
use
imagej
softwar
http
rsbwebnihgovij
skip
effici
calcul
use
follow
formula
intens
skip
band
intens
skip
band
intens
unskip
band
result
pcr
band
extract
use
gel
extract
kit
qiagen
direct
sequenc
pcr
product
perform
biomatrix
laboratori
co
ltd
chiba
japan
least
ten
cryosect
cut
flashfrozen
muscl
interv
serial
section
stain
polyclon
rabbit
antibodi
dystrophin
rod
domain
gift
dr
qilong
lu
carolina
medic
center
charlott
nc
usa
monoclon
mous
antibodi
development
mhc
leica
biosystem
newcastl
upon
tyne
uk
monoclon
rat
antibodi
abcam
cambridg
uk
antilaminin
polyclon
rabbit
antibodi
sigmaaldrich
molecular
probe
cambridg
uk
use
secondari
antibodi
dapi
contain
mount
agent
vectashield
vector
laboratori
burlingam
ca
usa
use
nuclear
counterstain
maximum
number
dystrophinposit
fiber
one
section
count
ta
muscl
fiber
size
evalu
use
fluoresc
microscop
keyenc
osaka
japan
hematoxylin
eosin
stain
perform
use
harri
hematoxylin
eosin
muscl
protein
cryosect
extract
lysi
buffer
describ
previous
total
protein
load
onto
xv
pantera
gel
drc
tokyo
japan
sampl
transfer
onto
immobilon
polyvinyliden
fluorid
membran
millipor
billerica
usa
semidri
blot
h
membran
incub
ctermin
monoclon
antibodi
leica
biosystem
newcastl
ltd
room
temperatur
h
bound
primari
antibodi
detect
horseradish
peroxidaseconjug
goat
antimous
igg
cedarlan
burlington
usa
supersign
chemiluminesc
substrat
pierc
rockford
il
usa
antibodi
use
load
control
signal
intens
detect
band
blot
quantifi
use
imagej
softwar
normal
load
control
dna
probe
tail
situ
hybrid
synthes
nihon
gene
research
laboratori
inc
sendai
japan
list
tabl
least
ten
cryosect
cut
flashfrozen
muscl
section
fix
paraformaldehyd
min
dehydr
h
section
incub
hcl
n
min
subject
pretreat
proteinas
k
min
section
fix
paraformaldehyd
min
room
temperatur
incub
glycin
mgml
min
next
section
subject
incub
h
prehybrid
solut
deioniz
formamid
ssc
buffer
section
hybrid
h
hybrid
solut
contain
digoxigeninlabel
probe
section
wash
sequenti
min
ssc
ssc
ssc
final
wash
ssc
min
detect
digoxigeninlabel
probe
phosphatas
roch
nbtbcip
stock
solut
roch
use
accord
manufactur
instruct
develop
slide
counterstain
hematoxylineosin
situ
hybrid
solut
contain
formamid
sigmaaldrich
mm
tri
ph
denhardt
solut
mm
edta
dextran
sulfat
pharmacia
bask
ridg
nj
usa
nacl
mg
salmon
dna
mg
yeast
trna
statist
differ
assess
oneway
analysi
varianc
differ
among
group
assess
tukey
comparison
fisher
exact
test
data
report
mean
valu
sd
sem
level
signific
set
p
supplementari
materi
avail
hmg
onlin
conflict
interest
statement
none
declar
work
support
intramur
research
grant
neurolog
psychiatr
disord
nation
center
neurolog
psychiatri
health
labour
scienc
research
grant
translat
research
health
labour
scienc
research
grant
translat
research
comprehens
research
disabl
health
welfar
ministri
health
labour
welfar
japan
mrc
confid
concept
award
